US FDA approves Pfizer’s drug for rare bleeding disorder

(Reuters) -The U.S. Food and Drug Administration approved Pfizer’s once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.

The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older.

The disorder primarily affects men and causes spontaneous and potentially severe bleeding after injuries or surgery. It impacts an estimated 33,000 men in the United States, according to government data.

Hympavzi is Pfizer’s second hemophilia treatment to receive FDA approval this year after the agency greenlit its hemophilia B gene therapy Beqvez in April.

(Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; Editing by Vijay Kishore)